India · Delayed Price · Currency is INR Dr. Lal PathLabs Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw double-digit revenue and EBITDA growth, driven by volume gains, network expansion, and strong B2C performance. Outlook for FY 2027 is early to mid-teens revenue growth with stable margins, supported by continued investment and broad-based regional momentum.
-
Revenue grew 10.6% YoY in Q3 FY26, with strong EBITDA margin of 27.2% and robust cash reserves. Preventive health packages and digital initiatives drove growth, while patient volume was impacted by lower seasonal fever cases. Management maintains 11%-12% organic growth guidance.
-
Q2 FY26 saw 10.7% revenue growth and 16.4% PAT growth year-over-year, with strong margins and broad-based performance. Investments in digital, AI, and high-end diagnostics, plus disciplined network expansion, support sustained growth. Interim dividend and 1:1 bonus issue announced.
-
Q1 FY26 saw 11.3% revenue growth and 24.3% profit after tax increase, driven by higher volumes, favorable test mix, and expansion in bundled and specialized testing. Guidance for 11–12% revenue growth is maintained, with margins expected to remain strong.
Fiscal Year 2025
-
Revenue grew 10.5% in FY 2025, outpacing industry, with strong expansion in labs and digital infrastructure. FY 2026 guidance targets 11-12% revenue growth and ~27% EBITDA margin, as investments continue in new geographies and advanced diagnostics.
-
Q3 FY25 saw 10.7% revenue growth, strong Delhi NCR performance, and Swasthfit packages up 27.2% YoY. Expansion continues in Tier 2/3/4 markets, with a focus on volume growth, digital infrastructure, and high-end diagnostics. Net cash stands at INR 1,123 crore.
-
Q2 FY25 saw 9.8% revenue growth and 18.1% PAT growth, driven by bundled test packages and network expansion, with margins and cash position remaining strong. Guidance for FY25 is maintained at or above last year’s growth, with continued investments in technology and expansion.
-
Q1 FY 2025 saw 11.3% revenue growth, strong profitability, and robust expansion in Tier 3/4 towns. Suburban Diagnostics integration and digital investments are progressing, with specialized and wellness portfolios driving growth. Cash reserves support dividends, acquisitions, and infrastructure.